Vimpat under threat as UCB fights generic launches
This article was originally published in Scrip
Executive Summary
UCB is suing Actavis, Novartis' Sandoz subsidiary and more than 13 other generics companies for patent infringement over their plans to market generic versions of the epilepsy drug Vimpat (lacosamide) in the US. In June, UCB filed a similar lawsuit in the US concerning Vimpat against Teva.